Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) Director Kurt M. Eichler bought 7,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 9th. The shares were acquired at an average price of $8.69 per share, with a total value of $60,830.00. Following the acquisition, the director now owns 437,990 shares of the company’s stock, valued at $3,806,133.10. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) opened at 8.425 on Tuesday. The company’s market cap is $65.44 million. Spring Bank Pharmaceuticals Inc has a 12-month low of $7.47 and a 12-month high of $13.25. The firm has a 50-day moving average price of $10.65 and a 200-day moving average price of $10.66.

Insider Buying and Selling by Quarter for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

A number of equities analysts recently commented on SBPH shares. William Blair started coverage on Spring Bank Pharmaceuticals in a report on Friday, August 19th. They set an “outperform” rating and a $26.00 target price for the company. Dawson James restated a “buy” rating on shares of Spring Bank Pharmaceuticals in a report on Sunday, November 6th.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of therapeutics using its small molecule nucleic acid hybrid (SMNH), chemistry platform. Its SMNH compounds are small segments of nucleic acids that the Company designs to selectively target and modulate the activity of specific proteins implicated in various disease states.

5 Day Chart for NASDAQ:SBPH

Receive News & Stock Ratings for Spring Bank Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.